Cargando…
Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework
BACKGROUND: This report describes how we refined a protocol for a pragmatic comparative effectiveness study of two models of an evidence-based diabetes shared medical appointment intervention and used the PRECIS-2 rating system to evaluate these adaptations. METHODS: We report primary data collected...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486627/ https://www.ncbi.nlm.nih.gov/pubmed/34598702 http://dx.doi.org/10.1186/s12913-021-07084-x |
_version_ | 1784577782736486400 |
---|---|
author | Glasgow, Russell E. Gurfinkel, Dennis Waxmonsky, Jeanette Rementer, Jenny Ritchie, Natalie D. Dailey-Vail, Jennifer Hosokawa, Patrick Dickinson, L. Miriam Kwan, Bethany M. |
author_facet | Glasgow, Russell E. Gurfinkel, Dennis Waxmonsky, Jeanette Rementer, Jenny Ritchie, Natalie D. Dailey-Vail, Jennifer Hosokawa, Patrick Dickinson, L. Miriam Kwan, Bethany M. |
author_sort | Glasgow, Russell E. |
collection | PubMed |
description | BACKGROUND: This report describes how we refined a protocol for a pragmatic comparative effectiveness study of two models of an evidence-based diabetes shared medical appointment intervention and used the PRECIS-2 rating system to evaluate these adaptations. METHODS: We report primary data collected between June and August 2019, and protocol refinements completed between 2018 and 2020. Twenty-two members of the study team collaborated in protocol refinement and completed the PRECIS-2 ratings of study pragmatism. We discuss study design refinements made to achieve the desired level of pragmatism vs. experimental control for each of the nine PRECIS-2 dimensions. Study team members received training on PRECIS-2 scoring and were asked to rate the study protocol on the nine PRECIS-2 dimensions. Ratings were compared using descriptive statistics. RESULTS: In general, the PRECIS-2 ratings revealed high levels of pragmatism, but somewhat less pragmatic ratings on the categories of Delivery and Organization (costs and resources). This variation was purposeful, and we provide the rationale for and steps taken to obtain the targeted level of pragmatism on each PRECIS-2 dimension, as well as detail design changes made to a) make the design more pragmatic and b) address COVID-19 issues. There was general agreement among team members and across different types of stakeholders on PRECIS-2 ratings. CONCLUSIONS: We discuss lessons learned from use of PRECIS-2 and experiences in refining the study to be maximally pragmatic on some dimensions and less so on other dimensions. This paper expands on prior research by describing actions to achieve higher levels of pragmatism and revise our protocol fit to the changed context. We make recommendations for future use of PRECIS-2 to help address changing context and other strategies for the planning of and transparent reporting on pragmatic research and comparative effectiveness research. TRIAL REGISTRATION: Clinicaltrials.gov Registration ID: NCT03590041. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-07084-x. |
format | Online Article Text |
id | pubmed-8486627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-84866272021-10-04 Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework Glasgow, Russell E. Gurfinkel, Dennis Waxmonsky, Jeanette Rementer, Jenny Ritchie, Natalie D. Dailey-Vail, Jennifer Hosokawa, Patrick Dickinson, L. Miriam Kwan, Bethany M. BMC Health Serv Res Research BACKGROUND: This report describes how we refined a protocol for a pragmatic comparative effectiveness study of two models of an evidence-based diabetes shared medical appointment intervention and used the PRECIS-2 rating system to evaluate these adaptations. METHODS: We report primary data collected between June and August 2019, and protocol refinements completed between 2018 and 2020. Twenty-two members of the study team collaborated in protocol refinement and completed the PRECIS-2 ratings of study pragmatism. We discuss study design refinements made to achieve the desired level of pragmatism vs. experimental control for each of the nine PRECIS-2 dimensions. Study team members received training on PRECIS-2 scoring and were asked to rate the study protocol on the nine PRECIS-2 dimensions. Ratings were compared using descriptive statistics. RESULTS: In general, the PRECIS-2 ratings revealed high levels of pragmatism, but somewhat less pragmatic ratings on the categories of Delivery and Organization (costs and resources). This variation was purposeful, and we provide the rationale for and steps taken to obtain the targeted level of pragmatism on each PRECIS-2 dimension, as well as detail design changes made to a) make the design more pragmatic and b) address COVID-19 issues. There was general agreement among team members and across different types of stakeholders on PRECIS-2 ratings. CONCLUSIONS: We discuss lessons learned from use of PRECIS-2 and experiences in refining the study to be maximally pragmatic on some dimensions and less so on other dimensions. This paper expands on prior research by describing actions to achieve higher levels of pragmatism and revise our protocol fit to the changed context. We make recommendations for future use of PRECIS-2 to help address changing context and other strategies for the planning of and transparent reporting on pragmatic research and comparative effectiveness research. TRIAL REGISTRATION: Clinicaltrials.gov Registration ID: NCT03590041. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-021-07084-x. BioMed Central 2021-10-02 /pmc/articles/PMC8486627/ /pubmed/34598702 http://dx.doi.org/10.1186/s12913-021-07084-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Glasgow, Russell E. Gurfinkel, Dennis Waxmonsky, Jeanette Rementer, Jenny Ritchie, Natalie D. Dailey-Vail, Jennifer Hosokawa, Patrick Dickinson, L. Miriam Kwan, Bethany M. Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title | Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title_full | Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title_fullStr | Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title_full_unstemmed | Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title_short | Protocol refinement for a diabetes pragmatic trial using the PRECIS-2 framework |
title_sort | protocol refinement for a diabetes pragmatic trial using the precis-2 framework |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486627/ https://www.ncbi.nlm.nih.gov/pubmed/34598702 http://dx.doi.org/10.1186/s12913-021-07084-x |
work_keys_str_mv | AT glasgowrusselle protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT gurfinkeldennis protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT waxmonskyjeanette protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT rementerjenny protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT ritchienatalied protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT daileyvailjennifer protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT hosokawapatrick protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT dickinsonlmiriam protocolrefinementforadiabetespragmatictrialusingtheprecis2framework AT kwanbethanym protocolrefinementforadiabetespragmatictrialusingtheprecis2framework |